{"nctId":"NCT00662675","briefTitle":"A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency","startDateStruct":{"date":"2008-08"},"conditions":["Exocrine Pancreatic Insufficiency","Steatorrhea","Malabsorption Syndromes","Cystic Fibrosis"],"count":40,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: Pancrease MT 10.5, or MT 21"]},{"label":"002","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo for Pancrease MT 10.5 or MT 21"]}],"interventions":[{"name":"Pancrease MT 10.5, or MT 21","otherNames":[]},{"name":"Placebo for Pancrease MT 10.5 or MT 21","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a diagnosis of CF documented by sweat chloride results (\\>60 mmol/L) and require pancreatic enzyme replacement therapy (PERT) to control clinical symptoms of EPI (nausea, vomiting, bloating, diarrhea, and abdominal pain) with a history of excess fat in the feces\n* Have documentation of an abnormal COA-fat and a fecal elastase result of \\<100 micrograms fecal elastase/gram stool\n* Must be on a stable diet and dose of pancreatic enzyme supplementation that has provided satisfactory symptom control for at least the past 1 month\n\nExclusion Criteria:\n\n* No extreme physical wasting with loss of weight and muscle mass\n* No severe, acute, or chronic pulmonary disease unrelated to complications of CF\n* No worsening of pulmonary disease in past 30 days\n* No use of drugs known to affect blood uric acid concentrations (e.g., aspirin, diflunisal, allopurinol, probenecid, thiazide diuretics, phenylbutazone, sulfinpyrazone)\n* No known congenital (present at birth) abnormalities of the gastrointestinal tract, heart, or liver\n* No distal intestinal obstruction syndrome (DIOS)","healthyVolunteers":false,"sex":"ALL","minimumAge":"7 Years","maximumAge":"60 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in the Coefficient of Fat Absorption (COA-fat Percent)","description":"Change in the coefficient of fat absorption (percent COA-fat) from the 72-hour inpatient period in the open-label phase to the 72-hour period inpatient period in the double-blind (withdrawal) phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.1","spread":"23.03"},{"groupId":"OG001","value":"-1.5","spread":"5.88"}]}]}]},{"type":"SECONDARY","title":"Change in Percent COA-Protein (Nitrogen)","description":"The change in percent COA-protein from the stool collection period in double-blind phase to open-label phase","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.5","spread":"15.3"},{"groupId":"OG001","value":"1.3","spread":"4.71"}]}]}]},{"type":"SECONDARY","title":"Percent of Patients Reporting Clinical Signs and Symptoms of Exocrine Pancreatic Insufficiency (EPI) During the Double-Blind Phase","description":"Percent of patients reporting nausea, vomiting, bloating, diarrhea, oily/greasy stools, and abdominal pain signs and symptoms reported as Adverse events during the double-blind phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":["Abdominal pain","Abdominal pain upper","Diarrhoea","Flatulence","Abnormal faeces"]}}}